People with a likely history of depression who take varenicline (Chantix) do not report more severe mood symptoms, medication side effects, or less success quitting smoking compared to people with no history of depression taking this drug.
The findings by Group Health, Free & Clear, and SRI International researchers are reported in a Journal of General Internal Medicine article published online (http://www.springerlink.com/content/77207452k3822r3v/). The National Cancer Institute (NCI)-funded, randomized COMPASS trial tracked more than 1,100 Group Health patients receiving behavioral treatment and varenicline to quit smoking. It's the first "real-world" examination of varenicline use since the original Food and Drug Administration (FDA) studies that the manufacturer funded.
"People tend to feel more depressed or irritable while quitting smoking, especially if they have had depression before," said lead author Jennifer McClure, PhD, Group Health Center for Health Studies' associate director for research. "And concerns have been raised that varenicline may increase neuropsychiatric symptoms including depressed mood in people with prior depression." Yet she and colleagues found using varenicline didn't worsen mood symptoms such as depression, anxiety, or irritability in people with a likely history of depression compared to others. "Still," she added, "it's prudent for clinicians to follow the FDA's advice of closely monitoring patients on this drug."
Varenicline is the latest drug the FDA has approved to help tobacco users quit. It seems more effective than other cessation medications, McClure explained, but post-marketing surveillance and case reports have raised concerns about its side effects. These include depression, agitation, and suicidal thoughts and actions, especially in people with a history of psychiatric problems. This has led to several FDA adviso
|Contact: Rebecca Hughes|
Group Health Cooperative Center for Health Studies